Findings from the Lean review of our drug reimbursement review program

29 February 2024 - Last year, CADTH communicated several improvements to our drug reimbursement review program, including a Lean review ...

Read more →

Consultation on CADTH’s drug reimbursement review procedures

25 June 2020 - CADTH is inviting stakeholder feedback on a revised procedure for its drug reimbursement review processes (i.e., pan-Canadian ...

Read more →

The ‘Top 10’ challenges for health technology assessment: INAHTA viewpoint

28 November 2019 - The International Network of Agencies for Health Technology Assessment (INAHTA) spans the globe as a network of ...

Read more →

Details of Doug Ford government’s health care overhaul, including new super agency, coming Tuesday

26 February 2019 - The Ontario government will announce its long-rumoured overhaul of the province’s health care system on Tuesday, ...

Read more →

How procurement judges the value of medical technologies: a review of health care tenders

8 February 2019 - Procurement's important role in healthcare decision making has encouraged criticism and calls for greater collaboration with health ...

Read more →

Ethics in health technology assessment: a systematic review

9 October 2018 - Integration of ethics into health technology assessment remains challenging for HTA practitioners.  ...

Read more →

New from CADTH: procedural guidelines and a streamlined therapeutic review framework

27 June 2018 - Recent changes continue to strengthen the Pharmaceutical Reviews portfolio and help CADTH adapt quickly to the changing ...

Read more →

Gene therapy: international regulatory and health technology assessment activities and reimbursement status

28 March 2018 - There is widespread variation in the definition of gene therapy used by international regulatory bodies and a ...

Read more →

Revamp national cancer, mental health groups, panel tells minister

27 March 2018 - Dramatic overhaul urged to role of Ottawa and its arm's-length organizations in health care. ...

Read more →

How Ottawa's using a fake drug crisis to force through damaging pharmaceutical policy

16 January 2018 - There is no affordability crisis to justify expanding drug price regulation, or a new national government-run pharmacare ...

Read more →

Revised procedure for advance notification of pending CDR submissions and resubmissions

28 September 2017 - In September 2016, CADTH updated the advance notification procedure for the Common Drug Review. ...

Read more →

Proposed revisions to CADTH’s biosimilar review process

1 August 2017 - Given the type of data required to support biosimilar authorization differs from that required for a biologic ...

Read more →

Proposed revision to the procedure for the CADTH Common Drug Review and the CADTH Therapeutic Review Framework

13 July 2017 - CADTH is inviting stakeholder comments and feedback on proposed revisions to the Procedure for the CADTH Common ...

Read more →

Subsequent entry products for non-biological complex drugs

9 June 2017 - In order to reflect the current environment for subsequent entry non-biological complex drugs, CADTH, in consultation ...

Read more →

Health Minister launches high drug price consultations

16 May 2017 - Canadian drug spending has ballooned by 184% since 2000 as a share of gross domestic product. ...

Read more →